Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease (Diabetic Retinopathy)

FACULTY

Charles C. Wykoff, MD, PhD
Director of Research, Retina Consultants of Texas
Chairman of Research and Clinical Trials Subcommittee, Retinal Consultants of America
Deputy Chair of Ophthalmology, Blanton Eye Institute & Houston Methodist Hospital
Houston, TX

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of diabetic retinopathy (DR), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to DR management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to nonproliferative and proliferative retinopathy and the mainstays of treatment for retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of DR
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with DR
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/(CCM) is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Charles C. Wykoff, MD, PhD has provided the following disclosures:

  • Consultant: Acucela, Adverum Biotechnologies, Alimera Sciences, Allegro, Allergan, Apellis Pharmaceuticals, Arctic Vision, Bausch + Lomb, Bayer, Chengdu Kanghong Biotech, DORC, EyePoint Pharmaceuticals, Genentech, Gyroscope, Iveric Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Opthea, Oxurion, Palatin, PolyPhotonix, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO, Roche, and Takeda
  • Research support: Adverum, Aerie Pharmaceuticals, Alder Biopharmaceuticals, Apellis, Chengdu Kanghong Biotech, Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Ionis Pharmaceuticals, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, RecensMedical, Regeneron, REGENXBIO, Roche, Samsung Bioepis, Santen Pharmaceutical, Senju Pharmaceutical, and Xbrane Biopharma
  • Ownership/Stock: ONL Therapeutics, PolyPhotonix, RecensMedical, Visgenx

CME Content Review

The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: September 17, 2021

EXPIRATION DATE: September 17, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.